Compounds > pseudoberberine
Page last updated: 2024-11-12

pseudoberberine

Description

pseudoberberine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14707273
CHEMBL ID453368
MeSH IDM0582190

Synonyms (4)

Synonym
pseudoberberine
pseudoberberine chloride
CHEMBL453368
17,18-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(21),2,4(8),9,13,15,17,19-octaene;chloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID439080Upregulation of InsR mRNA expression in human liver HepG2 at 10 ug/mL after 8 hrs by RT-PCR relative to control2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor.
AID346769Reduction of blood cholesterol level in hyperlipidemic Sprague-Dawley rat at 300 mg/kg, po daily twice for 17 days relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346778Acute toxicity in Kunming mouse assessed as change in body weight at 1000 mg/kg, po2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID1654922Inhibition of cell proliferation of human KM12C cells incubated for 15 hrs by MTT assay
AID694188Increase in AMPKalpha phosphorylation in human HepG2 cells at 10 uM after 4 hrs by Western blot analysis relative to untreated control2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation.
AID346781Acute toxicity in Kunming mouse assessed as kidney damage upto 5000 mg/kg, po after 14 days by hematoxylin and eosin staining2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346771Induction of LDLR mRNA expression in hyperlipidemic Sprague-Dawley rat liver at 100 mg/kg, po daily twice for 17 days by RT-PCR relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346780Acute toxicity in Kunming mouse assessed as liver damage upto 5000 mg/kg, po after 14 days by hematoxylin and eosin staining2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346766Toxicity in hyperlipidemic Sprague-Dawley rat assessed as liver and kidney function abnormalities at 100 mg/kg, po daily twice for 30 days2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346777Acute toxicity in Kunming mouse assessed as change in body weight at 250 mg/kg, po2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346775Induction of LDLR mRNA expression in hyperlipidemic C57BL/6J mouse liver at 100 mg/kg, po daily twice for 21 days by RT-PCR relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346757Induction of LDLR protein expression in human HepG2 cells at 10 ug/mL after 12 hrs by flow cytometry2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346779Acute toxicity in Kunming mouse assessed as change in body weight at 5000 mg/kg, po after 2 to 3 days2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID694191Induction of AMPKalpha phosphorylation in human HepG2 cells at 10 uM by Western blot analysis relative to untreated control2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation.
AID346783Acute toxicity in po dosed Kunming mouse assessed as lung damage upto 5000 mg/kg, po after 14 days by hematoxylin and eosin staining2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID694192Induction of AMPKalpha phosphorylation in human HepG2 cells after 4 hrs by Western blot analysis relative to untreated control2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation.
AID346776Acute toxicity in po dosed Kunming mouse after 14 days2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346761Reduction of blood low density lipoprotein cholesterol level in hyperlipidemic Sprague-Dawley rat at 100 mg/kg, po daily twice2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346774Reduction of blood low density lipoprotein cholesterol level in hyperlipidemic C57BL/6J mouse at 100 mg/kg, po daily twice for 21 days relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346770Reduction of blood low density lipoprotein cholesterol level in hyperlipidemic Sprague-Dawley rat at 300 mg/kg, po daily twice for 17 days relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID694189Increase in total AMPKalpha level in human HepG2 cells at 10 uM after 4 hrs by Western blot analysis relative to untreated control2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation.
AID346785Acute toxicity in Kunming mouse assessed as colon damage upto 5000 mg/kg, po after 14 days by hematoxylin and eosin staining2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID694190Increase in AMPKalpha phosphorylation in human HepG2 cells at 10 uM after 4 hrs by Western blot analysis relative to untreated control relative to total AMPKalpha level2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation.
AID346763Induction of HMG-CoA reductase mRNA expression in hyperlipidemic Sprague-Dawley rat liver at 100 mg/kg, po daily twice for 30 days by RT-PCR2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346765Toxicity in hyperlipidemic Sprague-Dawley rat assessed as food intake reduction at 100 mg/kg, po daily twice for 30 days2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID439079Upregulation of LDLR mRNA expression in human liver HepG2 at 10 ug/mL after 8 hrs by RT-PCR relative to control2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor.
AID346755Induction of LDLR mRNA expression in human HepG2 cells after 12 hrs by RT-PCR assay relative to untreated control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID694187Up regulation of LDLR expression in human HepG2 cells at 10 uM after 12 hrs by RT-PCR relative to untreated control2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation.
AID694193Induction of AMPKalpha phosphorylation in rat L6 cells2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Synthesis and structure-activity relationship of berberine analogues in LDLR up-regulation and AMPK activation.
AID346772Induction of LDLR mRNA expression in hyperlipidemic Sprague-Dawley rat liver at 300 mg/kg, po daily twice for 17 days by RT-PCR relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346762Induction of LDLR mRNA expression in hyperlipidemic Sprague-Dawley rat liver at 100 mg/kg, po daily twice for 30 days by RT-PCR relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346773Reduction of blood cholesterol level in hyperlipidemic C57BL/6J mouse at 100 mg/kg, po daily twice for 21 days relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346760Reduction of blood cholesterol level in hyperlipidemic Sprague-Dawley rat at 100 mg/kg, po daily twice2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346782Acute toxicity in Kunming mouse assessed as heart damage upto 5000 mg/kg, po after 14 days by hematoxylin and eosin staining2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346759Reduction of blood low density lipoprotein cholesterol level in hyperlipidemic Sprague-Dawley rat at 100 mg/kg, po daily twice for 30 days relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID361587Upregulation of LDLR mRNA expression in human HepG2 cells after 8 hrs by RT-PCR relative to control2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators.
AID346767Reduction of blood cholesterol level in hyperlipidemic Sprague-Dawley rat at 100 mg/kg, po daily twice for 17 days relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346784Acute toxicity in Kunming mouse assessed as brain damage upto 5000 mg/kg, po after 14 days by hematoxylin and eosin staining2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346758Reduction of blood cholesterol level in hyperlipidemic Sprague-Dawley rat at 100 mg/kg, po daily twice for 30 days relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346768Reduction of blood low density lipoprotein cholesterol level in hyperlipidemic Sprague-Dawley rat at 100 mg/kg, po daily twice for 17 days relative to control2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
AID346764Toxicity in hyperlipidemic Sprague-Dawley rat assessed as weight loss at 100 mg/kg, po daily twice for 30 days2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships, and cholesterol-lowering efficacy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's1 (16.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
berberine
[no description available]		2.4620alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker
Berberine chloride (TN)
[no description available]		2.9740organic molecular entity
canadine, (s)-isomer
(S)-canadine : The (S)-enantiomer of canadine.		2.0510an (S)-7,8,13,14-tetrahydroprotoberberine;
canadine		plant metabolite
5,6-dihydro-9-hydroxy-10-methoxybenzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium chloride
[no description available]		2.0710alkaloid
ConditionIndicatedRelationship StrengthStudiesTrials
Elevated Cholesterol
[description not available]		02.4520
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		02.4520
Amnesia-Memory Loss
[description not available]		02.0410
Cognition Disorders
Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.		02.0410
Amnesia
Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)		02.0410
chemdatabank.com